Zhengqing Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhengqing Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Saber Amin Yavari
Department of Orthopedics, University Medical Center Utrecht, Utrecht 3508GA, the Netherlands
3 shared publications - Azin Khodaei
Department of Orthopedics, University Medical Center Utrecht, Utrecht 3508GA, the Netherlands
2 shared publications - Harrie Weinans
University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Lanfeng Huang
Department of Orthopedics, The Second Hospital of Jilin University, Changchun 130041, P.R. China
2 shared publications Liwei Zhu
The Second Hospital of Jilin University
2 shared publicationsYoubin Li
The Second Hospital of Jilin University
2 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Biodegradable Cu/Sr Co-Doped Hydroxyapatite Composite for Bone Defect Reconstruction: An In Vivo Study
Bone defect repair remains a significant challenge in the clinic, particularly in complex ischemic situations. Conventional bone substitutes typically fail due to defect geometries, impaired blood supply, or unbalanced degradation in coordination with new bone formation. To address these limitations, we developed a bioactive, injectable bone void filler. It consists of a poly(vinyl alcohol)/sodium alginate (PVA/SA) composite loaded with copper (Cu), strontium (Sr), and codoped with low-crystallinity hydroxyapatite (HA) granules. Specifically, HA codoped with 1 mol % Cu and 4 mol % Sr was hydrothermally synthesized at 120 °C and incorporated into a double-network PVA/SA hydrogel. The regenerative capacity of this composite was then evaluated by implanting preformed cylinders into a nonload-bearing rat femoral defect model for 4 and 8 weeks. Bone regeneration and neovascularization were assessed using micro-CT and immunohistology. In vivo tests demonstrated that this composite is replaced by bone. Micro-CT and histological evaluations of the in vivo results showed that the Cu/Sr codoped composite enhanced bone defect repair accompanied by enhanced early neovascularization, supporting coordinated vascular and bone tissue regeneration. Lastly, histological staining revealed unique healing patterns characterized by “bridge-like” bone restoration and “island-like” regeneration, offering a promising option for treating complex bone defects.
- 12 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Open AccessBiodegradable Cu/Sr Co-Doped Hydroxyapatite Composite for Bone Defect Reconstruction: An In Vivo Study
Bone defect repair remains a significant challenge in the clinic, particularly in complex ischemic situations. Conventional bone substitutes typically fail due to defect geometries, impaired blood supply, or unbalanced degradation in coordination with new bone formation. To address these limitations, we developed a bioactive, injectable bone void filler. It consists of a poly(vinyl alcohol)/sodium alginate (PVA/SA) composite loaded with copper (Cu), strontium (Sr), and codoped with low-crystallinity hydroxyapatite (HA) granules. Specifically, HA codoped with 1 mol % Cu and 4 mol % Sr was hydrothermally synthesized at 120 °C and incorporated into a double-network PVA/SA hydrogel. The regenerative capacity of this composite was then evaluated by implanting preformed cylinders into a nonload-bearing rat femoral defect model for 4 and 8 weeks. Bone regeneration and neovascularization were assessed using micro-CT and immunohistology. In vivo tests demonstrated that this composite is replaced by bone. Micro-CT and histological evaluations of the in vivo results showed that the Cu/Sr codoped composite enhanced bone defect repair accompanied by enhanced early neovascularization, supporting coordinated vascular and bone tissue regeneration. Lastly, histological staining revealed unique healing patterns characterized by “bridge-like” bone restoration and “island-like” regeneration, offering a promising option for treating complex bone defects.
- Open Access
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (28) , 25292-25308
Harnessing copper–strontium synergy in an injectable composite for multi-pathway bone regeneration
Fabrication of an injectable PVA/alginate dual-network hydrogel loaded with Cu/Sr-doped hydroxyapatite (HA). (A) Synthesis of Cu/Sr-HA. (B) Mechanism of crosslinking. (C) The composite promotes angiogenesis and bone regeneration.
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (28) , 25292-25308
Open AccessHarnessing copper–strontium synergy in an injectable composite for multi-pathway bone regeneration
Fabrication of an injectable PVA/alginate dual-network hydrogel loaded with Cu/Sr-doped hydroxyapatite (HA). (A) Synthesis of Cu/Sr-HA. (B) Mechanism of crosslinking. (C) The composite promotes angiogenesis and bone regeneration.
- Open Access
- 22 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (49) , 67491-67503
Biomolecule and Ion Releasing Mesoporous Nanoparticles: Nonconvergent Osteogenic and Osteo-immunogenic Performance
Immune-involved cell communications have recently been introduced as key role players in the fate of mesenchymal stem cells in making bone tissue. In this study, a drug delivery system for bone (re)generation based on copper-doped mesoporous bioactive glass nanoparticles (BGNPs) was developed to codeliver copper as a biologically active ion and icariin as an anti-inflammatory agent. This design was based on temporal inflammation fluctuations from proinflammatory to anti-inflammatory during bone generation. Three in vitro models were performed with human mesenchymal stem cells (hMSCs) to verify the osteo-immunomodulatory effects of released copper ions and icariin: nonstimulated, co-conditioned with macrophage medium and co-cultured with macrophages. Both icariin and copper showed increased levels of alkaline phosphatase activation, indicating a direct osteogenic effect. Copper-doped BGNPs showed the highest increase of osteo-immunogenic properties in a mineralization assay and also induced short-term inflammation. However, the mineralization dropped in copper doped BGNPs after loading with icariin due to copper-icariin chelate formation and inhibition of the early inflammatory phase in the immune-stimulated in vitro models. In the absence of copper, the direct osteogenic properties of icariin overtook its osteo-immunogenic inhibition and increased calcification. Overall, BGNPs doped with 5 mol % copper and no icariin showed the highest bone-forming capacity.
- 22 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (49) , 67491-67503
Open AccessBiomolecule and Ion Releasing Mesoporous Nanoparticles: Nonconvergent Osteogenic and Osteo-immunogenic Performance
Immune-involved cell communications have recently been introduced as key role players in the fate of mesenchymal stem cells in making bone tissue. In this study, a drug delivery system for bone (re)generation based on copper-doped mesoporous bioactive glass nanoparticles (BGNPs) was developed to codeliver copper as a biologically active ion and icariin as an anti-inflammatory agent. This design was based on temporal inflammation fluctuations from proinflammatory to anti-inflammatory during bone generation. Three in vitro models were performed with human mesenchymal stem cells (hMSCs) to verify the osteo-immunomodulatory effects of released copper ions and icariin: nonstimulated, co-conditioned with macrophage medium and co-cultured with macrophages. Both icariin and copper showed increased levels of alkaline phosphatase activation, indicating a direct osteogenic effect. Copper-doped BGNPs showed the highest increase of osteo-immunogenic properties in a mineralization assay and also induced short-term inflammation. However, the mineralization dropped in copper doped BGNPs after loading with icariin due to copper-icariin chelate formation and inhibition of the early inflammatory phase in the immune-stimulated in vitro models. In the absence of copper, the direct osteogenic properties of icariin overtook its osteo-immunogenic inhibition and increased calcification. Overall, BGNPs doped with 5 mol % copper and no icariin showed the highest bone-forming capacity.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4965
Abstract 4965: Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers
Background: Chromosome instability (CIN), characterized by frequent and ongoing loss or gain of chromosome number, is commonly observed in tumor cells. Although long recognized as a vulnerability of cancer cells, potential CIN-selective therapeutic targets have only recently been discovered. Genetic studies from multiple groups have identified the mitotic kinesin, KIF18A, as selectively essential for the proliferation of CIN and aneuploid cells. By targeting KIF18A genetically and with novel small molecule inhibitors here we present data supporting KIF18A as therapeutic target in CIN tumors. Methods and Materials: To explore the therapeutic potential of KIF18A, we evaluated the effects of KIF18A genetic depletion and small molecule inhibition in both CIN-positive and CIN-negative cell lines. Biochemical, cell proliferation and phenotypic assays were used to characterize the potency and cellular activity of reference and novel KIF18A small molecule inhibitors. Anti-tumor activity of KIF18A inhibitors was assessed in CIN-positive cell line xenograft models. Results: In triple negative breast and colorectal CIN positive cancer cell lines siRNA mediated KIF18A knockdown and small molecule inhibition of the KIF18A ATPase activity both lead to a reduction in proliferation associated with an increase in mitotic index and multi-polar spindles. Consistent with KIF18A knockdown, KIF18A inhibition results in increased spindle length and chromosome alignment defects. Importantly, these effects are not observed with KIF18A knockdown or KIF18A inhibition in non-transformed, near diploid cells. In vivo, treatment of CIN-positive xenograft tumors with potent, novel KIF18A inhibitors results in robust anti-tumor activity with minimal impact on body weight. Conclusions: Collectively our data support KIF18A as a therapeutic target and provide rationale for the continued development of potent selective small molecule KIF18A inhibitors for the treatment of CIN positive cancers. Citation Format: James D. Joseph, Katherine Schutt, Kira Fisher, Katelyn Queen, Olivia Budington, Weifeng Mao, Wei Liu, Zhengqing Zhu, Xiangping Zhang, Yisong Xiao, Kunmin Lai, Xiaohui Gu, Jason Stumpff, Fred Aswad. Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4965.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 4965
Abstract 4965: Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers
Background: Chromosome instability (CIN), characterized by frequent and ongoing loss or gain of chromosome number, is commonly observed in tumor cells. Although long recognized as a vulnerability of cancer cells, potential CIN-selective therapeutic targets have only recently been discovered. Genetic studies from multiple groups have identified the mitotic kinesin, KIF18A, as selectively essential for the proliferation of CIN and aneuploid cells. By targeting KIF18A genetically and with novel small molecule inhibitors here we present data supporting KIF18A as therapeutic target in CIN tumors. Methods and Materials: To explore the therapeutic potential of KIF18A, we evaluated the effects of KIF18A genetic depletion and small molecule inhibition in both CIN-positive and CIN-negative cell lines. Biochemical, cell proliferation and phenotypic assays were used to characterize the potency and cellular activity of reference and novel KIF18A small molecule inhibitors. Anti-tumor activity of KIF18A inhibitors was assessed in CIN-positive cell line xenograft models. Results: In triple negative breast and colorectal CIN positive cancer cell lines siRNA mediated KIF18A knockdown and small molecule inhibition of the KIF18A ATPase activity both lead to a reduction in proliferation associated with an increase in mitotic index and multi-polar spindles. Consistent with KIF18A knockdown, KIF18A inhibition results in increased spindle length and chromosome alignment defects. Importantly, these effects are not observed with KIF18A knockdown or KIF18A inhibition in non-transformed, near diploid cells. In vivo, treatment of CIN-positive xenograft tumors with potent, novel KIF18A inhibitors results in robust anti-tumor activity with minimal impact on body weight. Conclusions: Collectively our data support KIF18A as a therapeutic target and provide rationale for the continued development of potent selective small molecule KIF18A inhibitors for the treatment of CIN positive cancers. Citation Format: James D. Joseph, Katherine Schutt, Kira Fisher, Katelyn Queen, Olivia Budington, Weifeng Mao, Wei Liu, Zhengqing Zhu, Xiangping Zhang, Yisong Xiao, Kunmin Lai, Xiaohui Gu, Jason Stumpff, Fred Aswad. Targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4965.
- Open Access
- 1 October 2021
- Published by Elsevier in Materials & Design
- Vol. 208
Three-dimensionally printed porous biomimetic composite for sustained release of recombinant human bone morphogenetic protein 9 to promote osteointegration
- 1 October 2021
- Published by Elsevier in Materials & Design
- Vol. 208
Open AccessThree-dimensionally printed porous biomimetic composite for sustained release of recombinant human bone morphogenetic protein 9 to promote osteointegration
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 2379280
Study of Osteoarthritis‐Related Hub Genes Based on Bioinformatics Analysis
Osteoarthritis (OA) is a common cause of morbidity and disability worldwide. However, the pathogenesis of OA is unclear. Therefore, this study was conducted to characterize the pathogenesis and implicated genes of OA. The gene expression profiles of GSE82107 and GSE55235 were downloaded from the Gene Expression Omnibus database. Altogether, 173 differentially expressed genes including 68 upregulated genes and 105 downregulated genes in patients with OA were selected based on the criteria of ∣log fold‐change | >1 and an adjusted p value < 0.05. Protein‐protein interaction network analysis showed that FN1, COL1A1, IGF1, SPP1, TIMP1, BGN, COL5A1, MMP13, CLU, and SDC1 are the top ten genes most closely related to OA. Quantitative reverse transcription‐polymerase chain reaction showed that the expression levels of COL1A1, COL5A1, TIMP1, MMP13, and SDC1 were significantly increased in OA. This study provides clues for the molecular mechanism and specific biomarkers of OA.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 2379280
Open AccessStudy of Osteoarthritis‐Related Hub Genes Based on Bioinformatics Analysis
Osteoarthritis (OA) is a common cause of morbidity and disability worldwide. However, the pathogenesis of OA is unclear. Therefore, this study was conducted to characterize the pathogenesis and implicated genes of OA. The gene expression profiles of GSE82107 and GSE55235 were downloaded from the Gene Expression Omnibus database. Altogether, 173 differentially expressed genes including 68 upregulated genes and 105 downregulated genes in patients with OA were selected based on the criteria of ∣log fold‐change | >1 and an adjusted p value < 0.05. Protein‐protein interaction network analysis showed that FN1, COL1A1, IGF1, SPP1, TIMP1, BGN, COL5A1, MMP13, CLU, and SDC1 are the top ten genes most closely related to OA. Quantitative reverse transcription‐polymerase chain reaction showed that the expression levels of COL1A1, COL5A1, TIMP1, MMP13, and SDC1 were significantly increased in OA. This study provides clues for the molecular mechanism and specific biomarkers of OA.